22:57 , Apr 7, 2017 |  BioCentury  |  Emerging Company Profile

Up a notch

By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG’s molecules could treat more patients than therapies against individual Notch receptors or ligands, with less toxicity than other pan-Notch inhibitors. The...
08:00 , Mar 3, 2016 |  BC Innovations  |  Translation in Brief

Notching up differences

A study in Cancer Research from the University of Queensland suggests that Notch 4 might be an outlier in the Notch family of proteins that are commonly thought of as oncogenes. By showing Notch 4...